Acor­da shares tank as ap­peals court re­fus­es in­junc­tion against cheap Ampyra knock­offs

Acor­da has suf­fered a fresh set­back in its last-ditch at­tempt to stop a gener­ic ver­sion of its mul­ti­ple scle­ro­sis drug Ampyra from hit­ting the mar­ket and evis­cer­at­ing its sole sig­nif­i­cant ther­a­peu­tic fran­chise. A fed­er­al ap­peals court re­fused to is­sue a tem­po­rary in­junc­tion against copy­cat ver­sions of its drug un­til the court de­cides on its ap­peal of a dis­trict court rul­ing strip­ping away key patent pro­tec­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER